A rapid increase in coverage of COVID-19 vaccination, Central African Republic

Problem In 2021, Central African Republic was facing multiple challenges in vaccinating its population against coronavirus disease 2019 (COVID-19), including inadequate infrastructure and funding, a shortage of health workers and vaccine hesitancy among the population. Approach To increase COVID-19 vaccination coverage, the health ministry used three main approaches: (i) task shifting to train and equip existing community health workers (CHWs) to deliver COVID-19 vaccination; (ii) evidence gathering to understand people's reluctance to be vaccinated; and (iii) bundling of COVID-19 vaccination with the polio vaccination programme. Local setting Central African Republic is a fragile country with almost two thirds of its population in need of humanitarian assistance. Despite conducting two major COVID-19 vaccination campaigns, by January 2022 only 9% (503 000 people) of the 5 570 659 general population were fully vaccinated. Relevant changes In the 6 months from February to July 2022, Central African Republic tripled its coverage of COVID-19 vaccination to 29% (1 615 492 out of 5 570 659 people) by August 2022. The integrated polio­COVID-19 campaign enabled an additional 136 040 and 218 978 people to be vaccinated in the first and second rounds respectively, at no extra cost. Evidence obtained through surveys and focus group discussions enabled the health ministry to develop communication strategies to dispel vaccine hesitancy and misconceptions. Lessons learnt Task shifting COVID-19 vaccination to CHWs can be an efficient solution for rapid scaling-up of vaccination campaigns. Building trust with the community is also important for addressing complex health issues such as vaccine hesitancy. Collaborative efforts are necessary to provide access to COVID-19 vaccines for high-risk and vulnerable populations.

The first year of COVID-19 vaccine roll-out in Africa: challenges and lessons learned

Introduction: in the first year following the introduction of COVID-19 vaccines, only 6.8% of the total population in the 47 countries in the WHO African Region have received full vaccination. In an emergency context, the intra-action review helps countries to assess their progress and document what has worked and not worked. Methods: we reviewed and identified the key lessons and challenges documented in the reports from intra-action review of COVID vaccine roll out in 22 African countries. Results: all countries documented high level political commitment, but a serious shortage of COVID-19 vaccines and funding. Seven countries identified gaps in microplanning because of lack of funding or due to the unpredictability in the type and volume of vaccine supplies. The shortage of operational funding also affected training of health workers and hampered the expansion of service delivery. The countries implemented multi-channel communications and social mobilisation activities, alongside social media engagement and social listening. However, country capacity was limited in terms of timely responding to infodemics. Hesitancy among health workers and the general population was a challenge in most of the countries. Conclusion: countries have gained valuable experiences exploring various COVID-19 vaccination delivery models, including implementing the integration of COVID-19 vaccination within routine health care programs. There is a need to regularly monitor or do studies measuring public perceptions towards COVID-19 vaccination in order to drive the demand generation efforts, as well as use evidence in addressing hesitancy

The covid-19 pandemic: research and health development in the World Health Organisation Africa region

Concerns have been expressed about the view point of WHO AFRO concerning research for health in the African Region. WHO AFRO considers research a critical component in the improvement of health in the Africa region. Ensuring the effectiveness of our strategies, policies and programmes requires evidence. In the context of the ongoing COVID-19 outbreak, WHO research interests cover key areas of the response. The WHO AFRO consider research as critical in our efforts at protecting people against health emergencies and pandemics like the COVID-19 and ensuring universal access to proven interventions. In view of this, the WHO has taken steps to strengthen capacity for research in the region. The results of these efforts may take time to manifest but will surely do as we persist in our drive, with support from our partners

The status of hepatitis B control in the African region

The World Health Organization (WHO) African Region has approximately 100 million people with chronic hepatitis B virus (HBV) infection. This review describes the status of hepatitis B control in the Region. We present hepatitis B vaccine (HepB) coverage data and from available data in the published literature, the impact of HepB vaccination on hepatitis B surface antigen (HBsAg) prevalence, a marker of chronic infection, among children, HBsAg prevalence in pregnant women, and risk of perinatal transmission. Lastly, we describe challenges with HepB birth dose (HepB-BD) introduction reported in the Region, and propose strategies to increase coverage. In 2015, regional three dose HepB coverage was 76%, and 16(34%) of 47 countries reported ≥ 90% coverage. Overall, 11 countries introduced HepB-BD; only nine provide universal HepB-BD, and of these, five reported ≥ 80% coverage. From non-nationally representative serosurveys among children, HBsAg prevalence was lower among children born after HepB introduction compared to those born before HepB introduction. However, some studies still found HBsAg prevalence to be above 2%. From limited surveys among pregnant women, the median HBsAg prevalence varied by country, ranging from 1.9% (Madagascar) to 16.1% (Niger); hepatitis B e antigen (HBeAg) prevalence among HBsAg-positive women ranged from 3.3% (Zimbabwe) to 28.5% (Nigeria). Studies in three countries indicated that the risk of perinatal HBV transmission was associated with HBeAg expression or high HBV DNA viral load. Major challenges for timely HepB-BD administration were poor knowledge of or lack of national HepB-BD vaccination guidelines, high prevalence of home births, and unreliable vaccine supply. Overall, substantial progress has been made in the region. However, countries need to improve HepB3 coverage and some countries might need to consider introducing the HepB-BD to help achieve the regional hepatitis B control goal of < 2% HBsAg prevalence among children < 5 years old by 2020. To facilitate HepB-BD introduction and improve timely coverage, strategies are needed to reach both facility-based and home births. Strong political commitment, clear policy recommendations and staff training on HepB-BD administration are also required. Furthermore, high quality nationally representative serosurveys among children are needed to inform decision makers about progress towards the regional control goal

Routine Immunization in the WHO African Region: Progress; Challenges and Way Forward

Tremendous progress has been made in expanding immunization in the African Region over the last four decades. And immunization; together with other primary health care and development interventions; has impacted significantly on the annual number of deaths among children under five. However; an estimated 22 (4.3 million) of the infants globally remaining unimmunized are located in four countries of the African Region (Democratic Republic of the Congo; Ethiopia; Nigeria and South Africa). Challenges remain in reaching an estimated 20-30 of children across the Region. In addition to the traditional vaccines (DTP; measles; polio and tuberculosis) newer ones; such as for PCV and rotavirus; are being rolled out in the Region but uptake and coverage is slow and patchy both within and between countries. The new regional strategic plan for immunization 2014-2020 is intended to provide policy and programmatic guidance to Member States; in line with the 2011- 2020 GVAP; in order to optimize immunization services and assist countries to further strengthen their immunization programmes

Rotavirus Disease Burden in Africa and the Need to Accelerate Introduction of Vaccines

It is important to establish the burden of rotavirus disease before and after the introduction of a rotavirus vaccine. Regional effortshave focused on building an unequivocal evidence base for rotavirus diarrhoea to support decisionmaking and sustained investment in new vaccine introduction. WHO recommends routine use ofrotavirus vaccines in all countries; particularlyin those with high mortality attributable todiarrhoeal disease. In countries where diarrhoeal deaths account for more than 10 of mortality inchildren aged under five years; the introduction of the vaccine is strongly recommended. This article reviews the available literature and summarizesthe estimated number of deaths in children underfive years attributable to rotavirus diarrhoea in the WHO African Region. Based on the available data; it can be concluded that the rotavirus disease burden is very high and that the introduction of rotavirus vaccines should be accelerated in the Region

Update on Elimination of Epidemic Meningitis in the African Region

At the demand of the African ministries of health; a new conjugate vaccine was developed by Serum Institute of India Limited (SIIL) against meningococcal A meningitis; the germ responsible for more than 95 of the meningitis epidemics in Africa; through a partnership between WHO and PATH and; with the financial support from the Bill et Melinda Gates Foundation. The vaccine is being introduced in all the 26 countries of the meningitis belt between 2010 and 2016. So far; 153 million people have been vaccinated in 12 countries. The vaccine is efficacious; no case of meningococcal meningitis A has been identified among vaccinated individuals and in post-campaign carriage studies. The overall number of meningitis cases dropped sharply during epidemic seasons in the countries of the belt. The vaccine will be introduced via routine immunization by the end of 2015

Progress towards the Elimination of Maternal and Neonatal Tetanus

Over the last 25 years impressive progress has been made on the elimination of maternal and neonatal tetanus worldwide including in the African Region. In 1999 a global initiative was launched to eliminate it completely with a global target date of 2015. This article looks at the progress made across the African Region and the challenges remaining and strategies being implemented for those countries yet to achieve the goal

Surveillance for Diseases Targeted by new Vaccines: Progress; Challenges and Way Forward

Thirteen years ago; WHO-AFRO proposed the establishment of a sentinel disease surveillance network as part of efforts to improve surveillance for invasive bacterial diseases (IBD) including paediatric pneumonia and meningitis and rotavirus diarrhoea in all Member States as part of surveillance for vaccine-preventable diseases and in line with the regional strategy integrated disease surveillance and response (IDSR). This was prompted by the eminent availability of new and prospective vaccines against Haemophilus influenzae type b (Hib); Streptococcus pneumoniae (S. pneum); Neisseria meningitides (Nm) and rotavirus vaccines. The Regional Office for Africa developed guidelines and tools and standardized methodology; including cases definitions to be used to recruit eligible cases. This article outlines the challenges and results of this initiative to date and aims for the future

Immunization Monitoring and Vaccine-Preventable Diseases Surveillance Data Management in the African Region

Countries in the WHO African Regionhave well-established national immunization programmes and disease control programmes working towards the different goals for the control of vaccine-preventable diseases; and generating coverage and surveillance data. WHO provides technical support to standardize the approaches; methodology; and tools used for data management. The datasets are shared with WHO for purposes of monitoring the coverage and disease trends across the Region. This article reviews the methods WHO employs to build capacity in this field of data management across the Region and the resultant achievements and gaps. Despite the recent improvements in some aspects of data quality; important policy; technical and managerial gaps remain; which need to be addressed in order to ensure that the data coming out of these national programmes are of optimal quality

African vaccination week: platform for effective partnership to deliver multiple interventions in the African Region

African Vaccination Week (AVW) is an initiative of the countries in the World Health Organization African Region promoting equity and access to vaccination. The initiative focuses on reaching populations with limited access to regular health services. Available data from 2014 showed that countries took advantage of the initiative to conduct integrated delivery of multiple interventions; targeting those with limited access to regular health services. A majority of the countries integrated between five and six interventions and very few delivered single interventions. The most common integrated intervention was vitamin A supplementation; followed by de-worming. Other interventions included educational activities; supplementation minerals and provision of health services. Data on coverage of integrated interventions are shown in the article

The performance of routine immunization in selected African countries during the first six months of the COVID-19 pandemic

Introduction: following the declaration of the COVID-19 pandemic on 11 March 2020, countries started implementing strict control measures, health workers were re-deployed and health facilities re-purposed to assist COVID-19 control efforts. These measures, along with the public concerns of getting COVID-19, led to a decline in the utilization of regular health services including immunization.Methods: we reviewed the administrative routine immunization data from 15 African countries for the period from January 2018 to June 2020 to analyze the trends in the monthly number of children vaccinated with specific antigens, and compare the changes in the first three months of the COVID-19 pandemic.Results: thirteen of the 15 countries showed a decline in the monthly average number of vaccine doses provided, with 6 countries having more than 10% decline. Nine countries had a lower monthly mean of recipients of first dose measles vaccination in the second quarter of 2020 as compared to the first quarter. Guinea, Nigeria, Ghana, Angola, Gabon, and South Sudan experienced a drop in the monthly number of children vaccinated for DPT3 and/ or MCV1 of greater than 2 standard deviations at some point in the second quarter of 2020 as compared to the mean for the months January-June of 2018 and 2019.Conclusion: countries with lower immunization coverage in the pre-COVID period experienced larger declines in the number of children vaccinated immediately after the COVID-19 pandemic was declared. Prolonged and significant reduction in the number of children vaccinated poses a serious risk for outbreaks such as measles. Countries should monitor coverage trends at national and subnational levels, and undertake catch-up vaccination activities to ensure that children who have missed scheduled vaccines receive them at the earliest possible time